Skip to content
Review

Do progression-free survival benefits justify increased toxicity and treatment burden? A meta-regression analysis of phase III immune checkpoint inhibitor trials from a value-based oncology perspective.

Oct 2026 · Clinical and Translational Oncology · 0 citations · 37 references
Medicine

TL;DR

PFS showed a limited and treatment-type-dependent association with OS, and PFS gains frequently accompanied increased toxicity.

View source

Similar papers

Review Open access Sep 2026

Progression‐free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta‐analysis

The objective of this systematic review and meta‐analysis was to evaluate the validity of progression‐free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma. The MEDLINE, Embase, and Cochrane C...

Russell Leong, David Chen, Laith Almasri et al. · 0 citations
Review Oct 2026

Baseline ECOG Performance Status 0 Versus 1 as a Modifier of Treatment Benefit from Adding an Immune Checkpoint Inhibitor to Chemotherapy: A Systematic Review and Meta-Analysis.

BACKGROUND Immune checkpoint inhibitors (ICIs) added to chemotherapy are established in solid tumors, but most trials enroll patients with ECOG performance status (PS) 0-1 patients. Whether baseline PS modifies the relative benefit of adding an ICI has not been formally tested using a within-trial interaction analysis....

Wafa Ali Asaad, Salah Ameen Abdu, Yue-Ying Zhou et al. · 0 citations
Meta-analysis Open access Sep 2026

Before-treatment body mass index as a prognostic factor in cancer patients receiving immune checkpoint inhibitors: a systematic review and dose-response meta-analysis

Higher pretreatment BMI was associated with longer adjusted OS and PFS in patients receiving ICI therapy, with the most consistent favorable association observed for obesity, warranting cautious interpretation.

Si-Yu Sun, Jun-Hao Zhang, Yan Li et al. · 0 citations
Review Open access Sep 2026

Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials

Background Randomized evidence for immune checkpoint inhibition in resectable non-small-cell lung cancer has progressed from pathological response to mature survival outcomes. We examined exploratory directional alignment across endpoints and quantified clinical yield, treatment burden, and the extent of perioperative...

J. Dai, Meng-Ni Liu, Hu Li et al. · 0 citations
Meta-analysis Open access Sep 2026

Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)

Abstract Designing phase III oncology trials to demonstrate overall survival (OS) superiority may be challenging due to sample size, follow-up time, resources, and costs as compared to trials evaluating intermediate endpoints, which may or may not be reliable surrogates of OS. In this study, we investigate at scale the...

A. Sherry, N. Meimoun, A. Miller et al. · 0 citations
Review Open access Oct 2026

Second-line treatment selection for advanced hepatocellular carcinoma: a network meta-analysis with reconstructed survival curves and integrated benefit–risk assessment

Background Optimal second-line systemic therapy for advanced hepatocellular carcinoma (HCC) remains uncertain. This study compared the efficacy and safety of available second-line treatments after tyrosine kinase inhibitor (TKI) failure and explored treatment strategies after immune checkpoint inhibitor (ICI) exposure....

Xin-Ming Li, Gui-Lin Nie, Yao-Qun Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.